Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients

• Status: Completed
• Trial end date: 2018-07-27
• Target enrollment: 0
• Participant gender: All

Summary

Our goal is to determine whether daily oral administration of VPD-737 (5 mg) is effective and safe in treating moderate to severe pruritus in patients with Epidermolysis Bullosa (EB).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jean Yuh Tang
• Collaborators: Epidermolysis Bullosa Research Partnership; Menlo Therapeutics Inc.; Vyne Therapeutics Inc.
• Treatments: Neurokinin A; Neurokinin-1 Receptor Antagonists; Serlopitant; Substance P

Criteria

Inclusion Criteria:

• Clinical diagnosis of Epidermolysis Bullosa (EB) and pruritus

Exclusion Criteria:

• Chronic liver or renal disease